Teva Branded Pharm Company Profile

✉ Email this page to a colleague

TEVA BRANDED PHARM has thirty-four approved drugs.

There are sixty US patents protecting TEVA BRANDED PHARM drugs.

There are six hundred and eighty-six patent family members on TEVA BRANDED PHARM drugs in forty-one countries and thirty-nine supplementary protection certificates in fourteen countries.

International Patents:	686
US Patents:	60
Tradenames:	34
Ingredients:	20
NDAs:	34
Patent Litigation for Teva Branded Pharm:	See patent lawsuits for Teva Branded Pharm

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-002	Apr 3, 2017		RX	Yes	No	11,648,244*PED	⤷ Sign Up			Y	⤷ Sign Up
Teva Branded Pharm	DIAMOX	acetazolamide	TABLET;ORAL	008943-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No	10,022,510	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,155,737	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-002	Mar 26, 1993	4,258,062*PED	⤷ Sign Up
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018	6,701,917	⤷ Sign Up
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018	7,540,282	⤷ Sign Up
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014	5,776,432	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	0.1 mg/0.02 mg and 0.01 mg	➤ Subscribe	2009-11-16
➤ Subscribe	Tablets	0.15 mg/0.03 mg	➤ Subscribe	2004-03-29
➤ Subscribe	Tablets	1 mg/0.02 mg and 75 mg	➤ Subscribe	2006-04-17
➤ Subscribe	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg	➤ Subscribe	2013-07-10
➤ Subscribe	Tablets	0.15 mg/0.03 mg/0.01 mg	➤ Subscribe	2008-01-22

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2018091957	⤷ Sign Up
Japan	2006525358	⤷ Sign Up
Eurasian Patent Organization	200970907	⤷ Sign Up
Israel	223117	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1602370	09C0020	France	⤷ Sign Up	PRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028
0503785	CA 2011 00026	Denmark	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0502314	SPC/GB02/037	United Kingdom	⤷ Sign Up	PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0503785	91330	Luxembourg	⤷ Sign Up	CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.